Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
10 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The AIM-listed company said the tender offer would return up to £7,199,998 to shareholders at 269p per ordinary share. It also called a general meeting for 26 October 2026 to consider the proposal.
On Friday, Canopy Gwth (TSX: WEED ) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Canopy Growth reported a 13% increase in net
Volatus Aerospace (TSX: FLT ) held its second-quarter earnings conference call on Friday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Volatus Aerospace reported Q2 2026 revenue of $8.
On Thursday, Landmark Bancorp (NASDAQ: LARK ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary Landmark Bancorp Inc. reported record second quarter
Ford Motor Co. (NYSE: F ) shares are trading lower on Friday as investors weigh a mixed earnings follow-through and fresh analyst commentary on pricing and product mix. Ford Motor shares are under pressure. Why is F stock retreating? What Is Driving Ford’s Earnings Outlook? Ford’s latest update showed adjusted EPS of 4
Tempus AI Inc. (NASDAQ: TEM ) shares are trading lower on Friday as traders digest post-earnings reset in expectations. Tempus AI stock is trending lower. Why is TEM stock trading lower? What To Watch After Tempus AI’s Q2 Earnings Tempus reported second-quarter results after Thursday’s close, posting revenue of $382.5
Revenue: $9.48B (est $9.44B) EPS: $0.68 (est $0.74) Net Income: $1.23B Operating Income: $1.59B Operational EBITA: $1.93B (est $1.87B) Operational EBITA Margin: 20.2% (est 19.9%) Orders: $12.04B (est $10.52B) Adjusted Free Cash Flow: $1.15B Sees Q3 Comparable Revenue Growth In Low- To Mid-Teens Y/Y Sees FY Positive Boo
() -- Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday. Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) rem
() -- AbbVie's (ABBV) Q2 financial results are expected to be in line with expectations, RBC Capital Markets analysts said in a Friday note. The company is scheduled to report its Q2 financial results on July 31. Analysts said sentiment on AbbVie has changed significantly, especially after the recent Apogee deal, which
Guggenheim raised the firm's price target on AbbVie to $261 from $249 and keeps a Buy rating on the shares. The firm updated its model ahead of the Q2 earnings report.